The majority of patients with pulmonary arterial hypertension, except for a few special circumstances, will begin treatment on combination therapy, instead of monotherapy, because combination therapy has been shown in trials to ahve better outcomes, explained Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
The majority of patients with pulmonary arterial hypertension, except for a few special circumstances, will begin treatment on combination therapy, instead of monotherapy, because combination therapy has been shown in trials to ahve better outcomes, explained Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Transcript
How do you weigh the benefits of monotherapy versus combination therapy in patients with pulmonary hypertension?
I think nowadays, I wouldn't normally, I would no longer start monotherapy. I would start with combination therapy in pulmonary arterial hypertension, except in very special circumstances, such as you have a responder to nitric oxide—a vasoreactivity test, in other words—and they would go onto long-term treatment with calcium channel blockers. And there are a few other circumstances. Perhaps patients with portal hypertension or pulmonary veno-occlusive disease, one would use monotherapy.
But in the vast majority of patients with pulmonary arterial hypertension, I would use initial combination therapy, because it has been shown in clinical trials of initial combination that the outcomes are better and in sequential combination that the outcomes are better too. There are a small group of patients who've been on monotherapy for 5 or 10 years, and they're completely stable. And I wouldn't go around changing them at all. But the majority of patients now are going to be on combination therapy, if not initially, very quickly.
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Study Highlights BMP7 as a Potential Therapeutic Target for Ovarian Cancer
November 30th 2023High Bone Morphogenetic Protein 7 (BMP7) expression was significantly associated with aggressive phenotypes, including advanced grade, International Federation of Gynecology and Obstetrics stage, residual disease, and adverse overall survival.
Read More